25-(OH)VitD3, As a Risk Indicator in Diagnosis of Adenocarcinoma.
Curr Drug Targets. 2013 Aug 20.
Cai LL, Ye HM, Lv XN, Wu YL, Zhang HJ, Zheng LM, Tzeng CM.
Translational Medicine Research Center，School of Pharmaceutical Sciences，Xiamen University, and Department of Clinical Laboratory, Zhongshan Hospital Xiamen University, China. lmzheng2002 at yahoo.com.
Vitamin D (VitD) comes from sunlight exposure and food intake. Apart from regulating calcium homeostasis and bone function, its levels also associate with the presence of development of adenocarcinoma. VitD can interact with VitD receptor (VDR), which heterodimerizes with retinoic X receptor (RXR) and then induces transcription of proteins that function in cell proliferation, differentiation, apoptosis, and angiogenesis. We reviewed and discussed the genes and their associated polymorphisms involved in the correlation between development of adenocarcinoma and VitD deficiency to highlight how VitD may be instrumental in cancerization.
Furthermore, pilot epidemiological data show that the detection of 25-hydroxy-Vitamin D3 (36.5±10.7 nmol/L, n=129) vs (81.4±19.8 nmol/L, n=81 can be a promising approach in cancer diagnosis. In this review, we suggest that 25-hydroxy-Vitamin D3 can act as an indicator and/or risk assessment factor in early diagnosis, prognosis and treatment of adenocarcinoma.
PMID: 23962296
See also VitaminDWiki
Wikipedia clip
Cancer of a gland which secretes a substance
Adenocarcinomas can arise in many tissues of the body due to the ubiquitous nature of glands within the body.
''While each gland may not be secreting the same substance, as long as there is an exocrine function to the cell, it is considered glandular and its malignant form is therefore named adenocarcinoma.’’